Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
2
USD
|
+3.63%
|
|
+18.34%
|
+41.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.22
|
39.52
|
207.6
|
63.53
|
82.57
|
138
|
-
|
-
|
Enterprise Value (EV)
1 |
16.22
|
39.52
|
207.6
|
63.53
|
82.57
|
138
|
138
|
138
|
P/E ratio
|
-0.59
x
|
-2.19
x
|
-4.22
x
|
-1.37
x
|
-1.5
x
|
-2.18
x
|
-2.55
x
|
-23.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
38.4
x
|
3.78
x
|
-
|
6.12
x
|
234
x
|
425
x
|
18.5
x
|
1.75
x
|
EV / Revenue
|
38.4
x
|
3.78
x
|
-
|
6.12
x
|
234
x
|
425
x
|
18.5
x
|
1.75
x
|
EV / EBITDA
|
-0.73
x
|
-2.58
x
|
-6.19
x
|
-1.38
x
|
-
|
-1.92
x
|
-1.89
x
|
-19.2
x
|
EV / FCF
|
-785,991
x
|
-2,806,987
x
|
-6,240,309
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,890
|
10,185
|
27,791
|
29,009
|
58,560
|
69,011
|
-
|
-
|
Reference price
2 |
4.170
|
3.880
|
7.470
|
2.190
|
1.410
|
2.000
|
2.000
|
2.000
|
Announcement Date
|
3/26/20
|
3/23/21
|
3/14/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.422
|
10.46
|
-
|
10.39
|
0.353
|
0.3246
|
7.457
|
78.96
|
EBITDA
1 |
-22.34
|
-15.34
|
-33.54
|
-46.17
|
-
|
-71.7
|
-72.85
|
-7.2
|
EBIT
1 |
-22.98
|
-15.91
|
-34.02
|
-46.4
|
-54.92
|
-64.25
|
-61
|
-14.77
|
Operating Margin
|
-5,445.02%
|
-152.19%
|
-
|
-446.79%
|
-15,557.79%
|
-19,792.24%
|
-818%
|
-18.71%
|
Earnings before Tax (EBT)
1 |
-23.76
|
-16.23
|
-33.78
|
-45.34
|
-50.4
|
-62.19
|
-60.01
|
-13.8
|
Net income
1 |
-23.6
|
-16.22
|
-33.77
|
-45.34
|
-50.39
|
-62.19
|
-60.01
|
-13.98
|
Net margin
|
-5,593.13%
|
-155.18%
|
-
|
-436.53%
|
-14,274.5%
|
-19,159.4%
|
-804.75%
|
-17.7%
|
EPS
2 |
-7.030
|
-1.770
|
-1.770
|
-1.600
|
-0.9400
|
-0.9175
|
-0.7840
|
-0.0840
|
Free Cash Flow
|
-20.64
|
-14.08
|
-33.27
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-4,890.76%
|
-134.66%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/23/21
|
3/14/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
8.25
|
-
|
-
|
-
|
-
|
10.39
|
-
|
-
|
0.353
|
-
|
0.235
|
0.024
|
0.086
|
0.004
|
-
|
-
|
EBITDA
1 |
-4.15
|
-8.532
|
-12.3
|
-12.52
|
-13.49
|
-7.911
|
-12.71
|
-13.4
|
-12.44
|
-
|
-16.46
|
-17.6
|
-18.3
|
-19.2
|
-
|
-
|
EBIT
1 |
-
|
-8.64
|
-12.38
|
-12.58
|
-13.49
|
-7.95
|
-12.79
|
-13.56
|
-12.62
|
-15.96
|
-16.64
|
-15.65
|
-15.32
|
-15.49
|
-11.54
|
-11.39
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-76.55%
|
-
|
-
|
-3,573.65%
|
-
|
-7,079.15%
|
-65,223.62%
|
-17,814.34%
|
-387,358.25%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.7
|
-8.561
|
-12.15
|
-12.42
|
-13.24
|
-7.523
|
-11.95
|
-12.34
|
-11.34
|
-14.76
|
-15.49
|
-15.47
|
-15.44
|
-15.77
|
-11.54
|
-11.39
|
Net income
1 |
-4.69
|
-8.559
|
-12.15
|
-12.42
|
-13.24
|
-7.521
|
-11.95
|
-12.34
|
-11.34
|
-14.76
|
-15.49
|
-15.47
|
-15.44
|
-15.77
|
-11.54
|
-11.39
|
Net margin
|
-56.85%
|
-
|
-
|
-
|
-
|
-72.41%
|
-
|
-
|
-3,212.46%
|
-
|
-6,591.91%
|
-64,446.88%
|
-17,954.65%
|
-394,312.5%
|
-
|
-
|
EPS
2 |
-0.5800
|
-0.3100
|
-0.4400
|
-0.4400
|
-0.4600
|
-0.2600
|
-0.2900
|
-0.2200
|
-0.2000
|
-0.2500
|
-0.2300
|
-0.2220
|
-0.2200
|
-0.2200
|
-0.1600
|
-0.1600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/13/20
|
3/14/22
|
5/9/22
|
8/15/22
|
11/10/22
|
3/9/23
|
5/9/23
|
8/9/23
|
11/9/23
|
3/14/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-20.6
|
-14.1
|
-33.3
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-86.1%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.08
|
-
|
0.19
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
18.72%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/23/21
|
3/14/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Average target price
22.6
USD Spread / Average Target +1,030.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.84% | 138M | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|